NEW YORK, Sept. 12, 2018 /PRNewswire/ -- About Primary Sclerosing CholangitisPrimary sclerosing cholangitis is chronic liver disease that can occur either by itself or due to other diseases. The disease is characterized by the inflammation and thickening of the bile ducts. This obstructs bile flow, which may lead to other liver diseases.Read the full report: https://www.reportlinker.com/p05501557
Technavio's analysts forecast the Global Primary Sclerosing Cholangitis Treatment Market to grow at a CAGR of 3.57% during the period 2018-2022.Covered in this reportThe report covers the present scenario and the growth prospects of the primary sclerosing cholangitis treatment market. To calculate the market size, the report considers the revenue generated from the primary sclerosing cholangitis treatment across the globe.The market is divided into the following segments based on geography:• Americas• APAC• EMEATechnavio's report, primary sclerosing cholangitis treatment market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.Key vendors• Allergan• Glenmark• Impax Laboratories• Mylan• Teva PharmaceuticalsMarket driver• Rise in number of liver transplants and UDCA treatment• For a full, detailed list, view our reportMarket challenge• Poor understanding of PSG pathogenesis• For a full, detailed list, view our reportMarket trend• Development of affordable PSC drugs• For a full, detailed list, view our reportKey questions answered in this report• What will the market size be in 2022 and what will the growth rate be?• What are the key market trends?• What is driving this market?• What are the challenges to market growth?• Who are the key vendors in this market space?• What are the market opportunities and threats faced by the key vendors?• What are the strengths and weaknesses of the key vendors?You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.Read the full report: https://www.reportlinker.com/p05501557
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected]
US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/global-primary-sclerosing-cholangitis-treatment-market-2018-2022-300711303.html
SOURCE Reportlinker
